The association between antidepressant dosage titration and medication adherence among patients with depression

Depression and Anxiety

Volumn 29, Issue 6, 2012, Pages 506-514

  Wu, Chung Hsuen ^a   Farley, Joel F ^a   Gaynes, Bradley N ^b,c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

Author keywords

adherence; anxiety; depression; dose titration; major depressive disorder

Indexed keywords

AMFEBUTAMONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84862752878     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.21952     Document Type: Article

References (40)

1. Compton WM, Conway KP, Stinson FS, Grant BF,. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry 2006; 163: 2141-2147. (Pubitemid 46114235)
2. The National Alliance on Mental Illness (NAMI). Major depression FACT SHEET. In:, Duckworth K, editor. Arlington, VA: The National Alliance on Mental Illness; 2009: 1-3.
3. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003; 289: 3095-3105. (Pubitemid 37432885)
4. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602. (Pubitemid 40973434)
5. Gorman JM,. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996; 4: 160-168. (Pubitemid 27237367)
6. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder. Arlington, VA: American Psychiatric Association; 2004.
7. American Psychiatric Association. Practice Guideline for the Treatment for Patients with Panic Disorder. 2nd ed. Arlington, VA: American Psychiatric Association; 2009.
8. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Arlington, VA: American Psychiatric Association; 2010.
9. University of Michigan Health System. Guidelines for Clinical Care: Depression. Ann Arbor, MI: University of Michigan Health System; 2005.
10. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55: 1128-1132. (Pubitemid 28558286)
11. Sood N, Treglia M, Obenchain RL, et al. Determinants of antidepressant treatment outcome. Am J Manag Care 2000; 6: 1327-1336. (Pubitemid 32043656)
12. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33: 67-74.
13. Stein MB, Cantrell CR, Sokol MC, et al. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006; 57: 673-680.
14. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36: 578-584. (Pubitemid 34270268)
15. Masand PS,. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003; 25: 2289-2304. (Pubitemid 37076320)
16. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000; 157: 1-45.
17. Rao S, Zisook S,. Anxious depression: clinical features and treatment. Curr Psychiatry Rep 2009; 11: 429-36.
18. Camacho F, Kong MC, Sheehan DV, Balkrishnan R,. Expenditures associated with dose titration at initiation of therapy in patients with major depressive disorder: a retrospective analysis of a large managed care claims database. P T 2010; 35: 452-468.
19. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995; 23: 395-412. (Pubitemid 26003141)
20. Amodeo L, Castelli L, Leombruni P, et al. Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study. Support Care Cancer 2012; 20: 375-384.
21. Flint AJ,. Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents. Drugs Aging 1998; 13: 269-280. (Pubitemid 28493005)
22. Flint AJ, Gagnon N,. Diagnosis and management of panic disorder in older patients. Drugs Aging 2003; 20: 881-891. (Pubitemid 37340280)
23. Thomson Reuters,. MARKETSCAN® USER GUIDE: Commercial Claims and Encounters Medicare Supplemental and Coordination of Benefits. Ann Arbor, MI: Thomson Reuters (HealthCare) Inc; 2008.
24. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12. (Pubitemid 46161090)
25. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-2310.
26. Liu X, Tepper PG, Able SL,. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol 2011; 26: 173-180.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
28. Weiden PJ, Kozma C, Grogg A, Locklear J,. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-891. (Pubitemid 39025215)
29. SAS Institute Inc. SAS/STAT 9.2 User's Guide. Cary, NC: SAS Institute Inc; 2008.
30. Farley JF, Wang CC, Hansen RA, et al. Continuity of antipsychotic medication management for Medicaid patients with schizophrenia. Psychiatr Serv 2011; 62: 747-752.
31. Melartin TK, Rytsala HJ, Leskela US, et al. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry 2005; 66: 220-227. (Pubitemid 40314329)
32. Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006; 44: 300-303. (Pubitemid 43755432)
33. Katon W, Cantrell CR, Sokol MC, et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005; 165: 2497-2503. (Pubitemid 41720012)
34. Liu X, Gelwicks S, Faries DE, Able SL,. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder. Int Clin Psychopharmacol 2010; 25: 315-322.
35. Kniesner TJ, Powers RH, Croghan TW,. Provider type and depression treatment adequacy. Health Policy 2005; 72: 321-332. (Pubitemid 40614683)
36. Muzina DJ, Malone DA, Bhandari I, et al. Rate of non-adherence prior to upward dose titration in previously stable antidepressant users. J Affect Disord 2011; 130: 46-52.
37. Brown C, Battista DR, Bruehlman R, et al. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005; 43: 1203-1207. (Pubitemid 43012177)
38. Russell J, Kazantzis N,. Medication beliefs and adherence to antidepressants in primary care. N Z Med J 2008; 121: 14-20.
39. Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008; 46: 1125-1133.
40. Steiner JF, Prochazka AV,. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-116. (Pubitemid 27089212)